Immunic's Phase 3 PMS Plan Adds Risk Amid Going-Concern Overhang

What happened

Immunic announced plans to initiate a Phase 3 trial of vidofludimus calcium in progressive MS, with first patients expected in H1 2027, following mixed Phase 2 results. The Phase 2 CALLIPER study had missed its primary endpoint after ~120 weeks, though earlier biomarker trends (NfL) had been observed. Meanwhile, the company's lead pivotal program, ENSURE-1/2 in relapsing MS, is fully enrolled with top-line data expected by end-2026. Cash stands at $55.3M (as of 6/30/25) with management disclosing going-concern uncertainty, implying a funding gap well ahead of this new Phase 3 start. The decision to advance PMS despite the primary endpoint miss appears aggressive given the capital constraints and shifts incremental risk onto the balance sheet.

Implication

The planning of a Phase 3 PMS trial signal management's confidence in a biomarker-defined or subgroup benefit, but the primary endpoint miss raises questions about the probability of success and the rationale for committing additional resources. With only $55.3M in cash and substantial operating burn, funding this new trial without a partnership or additional capital will likely be highly dilutive, increasing downside risk. The primary value driver remains the ENSURE RMS readout by end-2026, and any distraction or capital allocation to PMS could compromise the company's ability to execute on that pivotal milestone. If ENSURE results are positive and financing is secured, the PMS program could represent optionality, but until then it is an unfunded liability. We maintain a NEUTRAL/HOLD stance and would only turn more constructive on evidence of non-dilutive financing or cleaner PMS data; a highly dilutive raise to fund PMS would be negative.

Thesis delta

The thesis remains largely unchanged, with NEUTRAL/HOLD rating predicated on ENSURE RMS data and financing execution. However, the announced Phase 3 PMS trial after a Phase 2 miss introduces additional capital requirements and clinical risk that were not fully incorporated, slightly tilting the risk/reward to the downside near term. We will watch for any partnering or financing announcements as critical signposts.